Agenus Inc. (NASDAQ:AGEN) Given Consensus Rating of "Hold" by Brokerages

Key Points

• Five brokerages give a consensus recommendation of Hold (1 sell, 2 hold, 2 buy) with an average 12‑month price target of $14.50.
• Agenus beat March‑quarter estimates—reporting $0.56 EPS vs. a −$1.27 estimate and $34.2M revenue vs. $28.1M expected—but remains unprofitable (negative ROE and net margin) and analysts project a full‑year EPS of −12.55.
• The stock recently traded at $3.43 (12‑month range $1.38–$7.34), has a market capitalization of $131.71 million, and about 61.46% of shares are held by institutional investors.

Agenus Inc. (NASDAQ:AGEN - Get Free Report) has been assigned a consensus recommendation of "Hold" from the five brokerages that are covering the company, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation and two have given a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $14.50.

A number of equities analysts recently weighed in on the stock. Weiss Ratings reiterated a "sell (e+)" rating on shares of Agenus in a research report on Monday, December 29th. Wall Street Zen upgraded shares of Agenus from a "hold" rating to a "buy" rating in a research report on Saturday, March 21st.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in the company. LPL Financial LLC lifted its position in Agenus by 20.3% in the fourth quarter. LPL Financial LLC now owns 23,326 shares of the biotechnology company's stock valued at $73,000 after purchasing an additional 3,943 shares during the period. EP Wealth Advisors LLC acquired a new position in Agenus during the 4th quarter worth approximately $31,000. Jump Financial LLC purchased a new position in shares of Agenus during the 2nd quarter worth approximately $55,000. Traynor Capital Management Inc. purchased a new position in shares of Agenus during the 3rd quarter worth approximately $50,000. Finally, R Squared Ltd acquired a new stake in shares of Agenus in the 4th quarter valued at approximately $41,000. 61.46% of the stock is owned by hedge funds and other institutional investors.

Agenus Stock Down 0.3%

AGEN traded down $0.01 on Friday, hitting $3.43. 79,379 shares of the company traded hands, compared to its average volume of 619,215. Agenus has a 12-month low of $1.38 and a 12-month high of $7.34. The company has a 50 day moving average of $3.20 and a 200-day moving average of $3.75. The stock has a market capitalization of $131.71 million, a PE ratio of -7.41 and a beta of 1.57.

Agenus (NASDAQ:AGEN - Get Free Report) last announced its earnings results on Monday, March 16th. The biotechnology company reported $0.56 earnings per share for the quarter, beating the consensus estimate of ($1.27) by $1.83. Agenus had a negative return on equity of 7.65% and a negative net margin of 2.67%.The company had revenue of $34.20 million for the quarter, compared to the consensus estimate of $28.10 million. On average, research analysts anticipate that Agenus will post -12.55 EPS for the current year.

Agenus Company Profile

Agenus, Inc NASDAQ: AGEN is a clinical-stage immuno-oncology company headquartered in Lexington, Massachusetts. The company focuses on the discovery and development of therapies designed to modulate the immune system's response to cancer. Leveraging proprietary platforms in checkpoint modulation, vaccine technology and adjuvant systems, Agenus aims to deliver combination regimens that enhance antitumor activity across a variety of solid tumors and hematological malignancies.

Agenus' pipeline includes monoclonal antibodies targeting immune checkpoints, cytokine-based therapeutics and vaccine candidates built on its engineered heat shock protein (HSP) platform.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.